Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

DiNardo

Showing results (891-900 of 1,482) with videos related to

Pageof 149
Sort By:
American Journal of Hematology|April 12, 2022
Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trialsKunhwa Kim, Marina Konopleva, Courtney D DiNardo, et al.
Cancer|July 13, 2021
Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclaxKunhwa Kim, Abhishek Maiti, Sanam Loghavi, et al.
Haematologica|July 22, 2017
Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndromeNaval Daver, Hagop Kantarjian, Guillermo Garcia-Manero, et al.
Frontiers in Antibiotics|March 18, 2026
Correction: Inclusion of patient-centered, non-microbiological endpoints and biomarkers in tuberculosis drug trialsAndrew R DiNardo, Wilbert Sabiiti, Stephen H Gillespie, et al.
The Lancet. Oncology|December 8, 2016
Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control studyKoichi Takahashi, Feng Wang, Hagop Kantarjian, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 25, 2024
Efficacy and Safety of Gilteritinib versus Sorafenib as Post-Transplant Maintenance in Patients With FLT3-ITD Acute Myeloid LeukemiaJason Yeh, Oren Pasvolsky, Rima M Saliba, et al.
Blood|August 12, 2024
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidineHartmut Döhner, Keith W Pratz, Courtney D DiNardo, et al.
Cancer|May 29, 2024
Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantationJayastu Senapati, Hagop M Kantarjian, Alexandre Bazinet, et al.
Nutrients|July 15, 2026
The Role of Polyunsaturated Fatty Acids (PUFAs) in the Primary Prevention of Allergic Diseases in Children: A Position Paper of the SIAIP Primary and Secondary Prevention of Allergic Diseases and Nutraceuticals CommitteesAngela Klain, Cristiana Indolfi, Giorgio Ciprandi, et al.
British Journal of Haematology|January 5, 2023
Genome-wide association study of early ischaemic stroke risk in Brazilian individuals with sickle cell disease implicates ADAMTS2 and CDK18 and uncovers novel lociEric Jay Earley, Shannon Kelly, Fang Fang, et al.
Pageof 149

Showing results (891-900 of 1,482) with videos related to

Sort By:
Pageof 149
American Journal of Hematology|April 12, 2022
Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trialsKunhwa Kim, Marina Konopleva, Courtney D DiNardo, et al.
Cancer|July 13, 2021
Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclaxKunhwa Kim, Abhishek Maiti, Sanam Loghavi, et al.
Haematologica|July 22, 2017
Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndromeNaval Daver, Hagop Kantarjian, Guillermo Garcia-Manero, et al.
Frontiers in Antibiotics|March 18, 2026
Correction: Inclusion of patient-centered, non-microbiological endpoints and biomarkers in tuberculosis drug trialsAndrew R DiNardo, Wilbert Sabiiti, Stephen H Gillespie, et al.
The Lancet. Oncology|December 8, 2016
Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control studyKoichi Takahashi, Feng Wang, Hagop Kantarjian, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 25, 2024
Efficacy and Safety of Gilteritinib versus Sorafenib as Post-Transplant Maintenance in Patients With FLT3-ITD Acute Myeloid LeukemiaJason Yeh, Oren Pasvolsky, Rima M Saliba, et al.
Blood|August 12, 2024
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidineHartmut Döhner, Keith W Pratz, Courtney D DiNardo, et al.
Cancer|May 29, 2024
Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantationJayastu Senapati, Hagop M Kantarjian, Alexandre Bazinet, et al.
Nutrients|July 15, 2026
The Role of Polyunsaturated Fatty Acids (PUFAs) in the Primary Prevention of Allergic Diseases in Children: A Position Paper of the SIAIP Primary and Secondary Prevention of Allergic Diseases and Nutraceuticals CommitteesAngela Klain, Cristiana Indolfi, Giorgio Ciprandi, et al.
British Journal of Haematology|January 5, 2023
Genome-wide association study of early ischaemic stroke risk in Brazilian individuals with sickle cell disease implicates ADAMTS2 and CDK18 and uncovers novel lociEric Jay Earley, Shannon Kelly, Fang Fang, et al.
Pageof 149